Searched for
TORRENT PHARMA RESULTS
Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...- Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...
- Red alert: 15 stocks most vulnerable to FII selling as DIIs refuse to step inForeign institutional investors have divested approximately $53 billion from Indian equities since September 2024, leading to significant o...
- Stocks in news: SBI, Titan, Hyundai, BSE, Torrent Pharma, Axis BankIndian markets saw volatile trading on Thursday, closing nearly unchanged despite positive signals. Several companies including SBI, Titan,...
- Semaglutide API price plunges amid GLP-1 rushGlobal demand for weight-loss drugs Ozempic and Wegovy has caused semaglutide prices to drop significantly. Manufacturing has expanded rapi...
- Torrent Pharma Q3 Results: Net profit jumps 14% to Rs 503 croreTorrent Pharma reported a 14% YoY rise in Q3FY25 net profit to ₹503 crore, driven by strong India sales growth of 12% and revenue momentum ...
- Torrent Pharma Q3 Results: Net profit jumps 52% YoY t Rs 443 croreThe company had reported a net profit of Rs 292 crore during the corresponding period of the previous year. Revenues rose 10% YoY to Rs 2,7...
- Torrent Pharma posts 24% jump in net profit to Rs 386 crore in Q2FY24India sales that constitute over half of Torrent's revenues grew 18% YoY to Rs 1,444 crores in Q2FY24. Torrent said the growth was led by c...
- Torrent Pharma Q1 Results: Profit rises 7% YoY to Rs 378 croreThe earnings before interest, tax, depreciation and amortisation (EBITDA) 11% YoY to Rs 791 crore. The R&D spend rose 6% YoY to Rs 129 cror...
- Torrent Pharma shares jump 8% on strong Q4 earnings. How to trade stock now?Torrent Pharmaceuticals' shares surged 8% after the company reported a profit of INR 287 crore ($38.4m) during Q4 FY22, compared to a net l...
- Torrent Pharma Q4 Results: Firm back in the black with PAT of Rs 287 cr; board okays Rs 5000 crore fund raiseRevenue rose 17% year-on-year (YoY) to Rs 2491 crore in Q4FY23. The company said the performance was led by robust growth across branded ma...
- Torrent Pharma Q2 Results: Firm posts 1% drop in PAT to Rs 312 croreRevenues rose 7% YoY to Rs 2,291 crore during Q2FY23
- Torrent Pharma Q2 Results: Firm posts 1% drop in net profit to Rs 312 croreRevenues rose 7% YoY to Rs 2,291 crore during Q2FY23, compared to Rs 2,137 crore in Q2FY22.
- Torrent Pharma posts Rs 354 cr net profit in Q1FY23, appoints Aman Mehta on the board"Further, he has led several organic growth initiatives that have started delivering market share gains, with a focus on new product launch...
- Torrent Pharma post Rs 118 crore net loss in Q4FY22The earnings before interest, tax, depreciation and amortisation (EBITDA) margins dropped 300 basis points YoY to 29% in Q1FY22.
- Torrent Pharma tanks 15% after disappointing Q3 numbersThe drugmaker said its consolidated net profit declined by 16 per cent to Rs 249 crore for the quarter ended December 2021. The company had...
- US business pulls down Torrent Pharma net profit by 16% in Q3FY22Revenues rose 6 per cent YoY to Rs 2,108 crore in Q3FY22 compared to Rs 1,995 crore in Q3FY21
- Torrent Pharma Q2 results: Consolidated net profit up 2% at Rs 316 croreNet sales increased to Rs 2,103 crore during the quarter under review from Rs 1,985 crore in the year-ago period, Torrent Pharma said in a ...
- Torrent Pharma Q1 results: Net profit up 2.8% to Rs 330 crConsolidated revenue from operations of the company stood at Rs 2,134 crore for the quarter under consideration. It was Rs 2,056 crore for ...
- Torrent Pharma Q3 profit rises 2% to Rs 251 croreConsolidated revenue from operations of the company stood at Rs 1,966 crore for the quarter under consideration.
Load More
